{"id":"NCT04209114","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer","officialTitle":"A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-05","primaryCompletion":"2023-06-07","completion":"2023-06-07","firstPosted":"2019-12-23","resultsPosted":"2024-06-27","lastUpdate":"2024-06-27"},"enrollment":114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bladder Cancer","Bladder Tumor","Muscle-Invasive Bladder Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["Opdivo","BMS-936558"]},{"type":"PROCEDURE","name":"Radical cystectomy (RC)","otherNames":[]},{"type":"BIOLOGICAL","name":"Bempegaldesleukin","otherNames":["BMS-986321","NKTR-214","Bempeg"]}],"arms":[{"label":"Arm A: Combination Therapy","type":"EXPERIMENTAL"},{"label":"Arm B: Monotherapy","type":"EXPERIMENTAL"},{"label":"Arm C: Standard-of-care","type":"OTHER"}],"summary":"The purpose of the study is to see if treatment with nivolumab plus bempegaldesleukin or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with high-risk urothelial cancer, including muscle-invasive bladder cancer who are not able to receive cisplatin chemotherapy.","primaryOutcome":{"measure":"Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care","timeFrame":"From time of radical cystectomy up to 100 days after last treatment (up to approximately 17 months)","effectByArm":[{"arm":"Arm A: Nivolumab + Bempegaldesleukin","deltaMin":10.8,"sd":null},{"arm":"Arm C: Standard of Care","deltaMin":2.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":116,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Israel","Italy","Mexico","Netherlands","Poland","Russia","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsclinicaltrials.com/us/en/home"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":37},"commonTop":["Pruritus","Fatigue","Pyrexia","Constipation","Asthenia"]}}